Cancer of the PROSTATE
Conditions
Brief summary
To assess the feasibility of acquiring an MR scan in the radiotherapy treatment position as part of the patient's radiotherapy pathway and incorporating the data into our radiotherapy planning systems, so that it can be potentially used to reduce healthy tissue exposure to radiation. Subsequently, the protocols and procedures established can be used to put the technique into routine clinical practice.
Detailed description
Conventional radiotherapy treatment planning uses computed tomography (CT) scans to provide an accurate 3-D picture of the local anatomy. This helps the planners to maximise the radiation dose delivered to the prostate, whilst minimising the dose to surrounding normal tissue. Magnetic resonance imaging (MRI) scanning is an established diagnostic imaging technique that provides even clearer images of the local anatomy. However, until recently the technology hasn't existed to allow us to perform MRI scans with patients set-up in the position required to plan and deliver radiotherapy to the prostate. This study is being performed to assess methods that may allow us to incorporate MRI scans into the radiotherapy planning process, which may further increase the accuracy of the treatment, reducing the irradiation of surrounding normal tissue and minimising toxicity.
Interventions
DEVICEMRI scan
MRI scan using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan
Sponsors
Guy's and St Thomas' NHS Foundation Trust
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written, voluntary, informed consent * Age ≥ 18 * ECOG Performance Status ≤ 2 * Life expectancy \> 12 months * Histologically proven carcinoma of the prostate * Radical radiotherapy +/- hormones indicated as the primary treatment modality * Staging diagnostic MRI of the prostate need to be available for comparison. * Adequate organ function and absence of other major concurrent illness, allowing
Exclusion criteria
* Inability to provide informed consent * Impaired renal function (serum creatinine of \> 200) * Severely impaired liver function * Patients with allergies or contra-indications to the gadolinium contrast agent that may be used in the study * Severe claustrophobia or inability to tolerate MRI scans * General contra-indications to MRI including cardiac pacemakers and defibrillators, metallic prosthetic devices, aneurysm clips and metal fragments in the eyes, as defined in MRI safety departmental protocols * Serious inter-current conditions or other non-malignant illnesses that are uncontrolled or whose control may be affected by participation in this study * Any patient who has urinary or faecal incontinence * Status greater than or equal to 3
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Standard Operating Procedure (SOP) for MRI-simulation for prostate patients | 6 months | Write a Standard Operating Procedure (SOP) for MRI-scanning of prostate patients in the radiotherapy treatment position so that their data can be used in the treatment planning for either in-direct or MRI-only planning |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Protocol for in-direct MRI planning for prostate | 6 months | Write a clinical protocol for in-direct MRI planning of prostate external beam radiotherapy, whereby MRI data is used to define anatomical structures and these are translated onto the co-registered CT scan for treatment planning |
| Clinical Protocol for direct MRI-only planning for prostate | 18 months | Write a clinical protocol for direct MRI-only planning of prostate external beam radiotherapy, whereby MRI data is used to define anatomical structures and also for dose calculation and setup verification |
Countries
United Kingdom
Outcome results
None listed